Option Circle | $3,000,000 | (Mar 12, 2026)
Standard Kernel Co. | $20,000,000 | (Mar 12, 2026)
Chowbus | $81,000,000 | (Mar 12, 2026)
Certified by Founder
Lodge
ArsenalBio
start up
United States
- South San Francisco , CA
- 09/09/2022
- Series B
- $220,000,000
ArsenalBio is a privately held, programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer. Our discovery engine comprises precise CRISPR-enabled genome editing, integrated circuits incorporating logic gates for improved tumor targeting, and therapeutic enhancements enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. Our team is engineering living medicines to attack cancer’s inherent multi-faceted nature and bring dramatic improvements to the lives of patients.
- Industry Biotechnology Research
- Website https://arsenalbio.com/
- LinkedIn https://www.linkedin.com/company/arsenalbio/
zymtrace | $12,200,000 | (Mar 12, 2026)
AgentMail (YC S25) | $6,000,000 | (Mar 12, 2026)
Ernesta Inc. | $20,000,000 | (Mar 12, 2026)
Translucent AI | $27,000,000 | (Mar 12, 2026)
Xscape Photonics Inc | $37,000,000 | (Mar 12, 2026)
Swarm Aero | $35,000,000 | (Mar 12, 2026)
anchr | $5,800,000 | (Mar 12, 2026)
Verdant Impact | $3,000,000 | (Mar 11, 2026)
Imperium Technologies, Inc | $2,000,000 | (Mar 11, 2026)